Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
🕑 1 min read
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Source: Business News — Read the original story
